期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

中国肿瘤护士在癌症症状管理中的新角色 被引量：11

The new role of Chinese oncology nurses in the management of cancer symptoms
下载PDF
导出
摘要 本文重点论述了癌痛的流行趋势、机制、管理、药物疗法、非药物疗法/补充疗法以及其他常见癌症症状(静脉炎、恶心呕吐等)及护理干预,肿瘤急症(高钙血症、败血症、上腔静脉压迫综合征、弥散性血管内凝血和脊髓压迫)的原因、治疗及护理措施,旨在说明中国肿瘤护士在癌症症状管理中的重要角色和地位。
作者 Mary Gullatte 焦杰
机构地区 美国护理科学院 不详
出处 《护士进修杂志》 2017年第14期1253-1257,共5页 Journal of Nurses Training
关键词 肿瘤 护士 癌症 症状管理 Tumor Nurses Cancer Symptom management
分类号 R471 [医药卫生—护理学] R473.73 [医药卫生—护理学]
  • 相关文献

参考文献2

二级参考文献24

  • 1Bai H,Mao L,Wang HS,et al.Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages ⅢB to IV non-small-cell lung cancer[J].J Clin Oncol 2009; 27:2653-9.
  • 2Brodowicz T,Krzakowski M,Zwitter M,et al.Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer:A phase Ⅲ trial[J].Lung Cancer 2006; 52:155-63.
  • 3Belani CP,Barstis J,Perry MC,et al.Multicenter,randomized trial for stage ⅢB or Ⅳ non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation[J].J Clin Oncol 2003; 21:2933-9.
  • 4Fidias P,Dakhil SR,Lyss AP,et al.Updated report of a phase Ⅲ study of induction therapy with gemcitabine + carboplatin (GC) followed by either delayed vs immediate second-line therapy with docetaxel (D) in advanced non-small cell lung cancer (NSCLC)[J].J Clin Oncol 2006; 24:7032.
  • 5Hida T,Okamoto I,Kashii T,et al.Randomized phase Ⅲ study of platinum-doublet chemotherapy followed by gefitinib versus continued platinum-doublet chemotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC):Results of West Japan Thoracic Oncology Group trial (WJTOG 0203).J Clin Oncol 2008; 26:LBA 8012.
  • 6Park JO,Kim SW,Ahn JS,et al.Phase Ⅲ trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer[J].J Clin Oncol 2007; 25:5233-9.
  • 7Fukuoka M,Yano S,Giaccone G,et al.Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer[J].J Clin Oncol 2003; 21:2237-46.
  • 8Thatcher N,Chang A,Parikh P,et al.Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer:results from a randomised,placebo-controlled,multicentre study (Iressa Survival Evaluation in Lung Cancer)[J].Lancet 2005; 366:1527-37.
  • 9Chang A,Parikh P,Thongprasert S,et al.Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer:subset analysis from the ISEL study[J].J Thorac Oncol 2006; 1:847-55.
  • 10Jackman DM,Yeap B,Sequist LV,et al.Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib[J].Clin Cancer Res 2006; 12:3908-14.

共引文献11

同被引文献105

引证文献11

二级引证文献72

护士进修杂志
2017年 第14期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部